Recce Scouts New Synthetic Anti-Infectives to Overcome Resistance

The MTPConnect Podcast

MTPConnect에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 MTPConnect 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

2+ y ago 36:09

MP3•에피소드 홈

It’s World Antimicrobial Awareness Week 2021 and we are shining a light on Australia’s expertise and innovations to fight superbugs.

In this episode we catch up with Recce Pharmaceuticals, a company out of Western Australia that is pioneering the development and commercialisation of a new class of synthetic anti-infectives designed to overcome resistance. Its lead compound is the only synthetic polymer and sepsis drug candidate in development, as listed in the Pew Charitable Trusts Global New Antibiotics in Development Pipeline and has been awarded the US regulator’s Fast Track Designation under the GAIN Act.

Recce Pharmaceuticals’ Chief Executive Officer James Graham, joins the podcast from the United States after attending the World Antimicrobial Resistance Congress in Washington DC.

Joining host Caroline Duell is Andrew Bowskill, MTPConnect’s Director of Stakeholder Engagement for Queensland and the co-chair of AAMRNet, Australia’s first industry led, multi-stakeholder Antimicrobial Resistance Network, established and operated by MTPConnect.

172 에피소드

#Science #Tech #Fitness #Medicine #MTPConnect #Health and Well-Being #Medtech #Pharma #Industries